Background Crooke cell adenomas (CCAs) are a rare, aggressive subset of secretory
pituitary corticotroph adenomas (sCTAs) found in 5%–10% of patients with Cushing disease …

In 2017, WHO published an updated classification of the pituitary adenomas according to
the lineages defined by the transcription factors, PIT1, SF1 and TPIT. Nomenclature of the …

Introduction Usually, prolactinomas are treated with dopamine agonists (DA). Surgery is
considered an option when the patient cannot bear or does not respond positively to DA …

Background Circulating plasma miRNAs have been increasingly studied in the field of
pituitary neuroendocrine tumor (PitNET) research. Our aim was to discover circulating …

Introduction Pituitary adenomas (PA) are slow‐growing, benign tumors that usually do not
metastasize to other body organs. Although they are referred to as benign, tumor growth can …

Context.—Pituitary neuroendocrine tumors/adenomas are common intracranial tumors that
require accurate subtyping because each tumor differs in its biologic behavior and response …

Purpose Acromegalic patients with giant growth hormone-secreting pituitary adenomas
(GHPAs)(≥ 40 mm) are relatively rare, and their clinical characteristics and treatment …

Innovation roadmaps are important, because they encourage the actors in an innovation
ecosystem to creatively imagine multiple possible science future (s), while anticipating the …

The aim of this multicenter prospective survey called PIT-EASY was to assess the relevance
of the European Pituitary Pathology Group (EPPG) diagnostic tools for pituitary …

The increase in life expectancy along with technological advances has translated into a
higher number of pituitary adenomas (PA) diagnosed from the age of 65. In the elderly …